UNITED STATES |
SECURITIES AND EXCHANGE COMMISSION |
WASHINGTON, DC 20549 |
|
|
FORM 8-K |
CURRENT REPORT PURSUANT |
TO SECTION 13 OR 15(D) OF THE |
SECURITIES EXCHANGE ACT OF 1934 |
|
Date of report (Date of earliest event reported):October 18, 2016 |
BIOTRICITY INC. |
(Exact Name of Registrant as Specified in Its Charter) |
Nevada |
| 333-201719 |
| 47-2548273 |
(State or Other Jurisdiction of Incorporation or Organization) |
| (Commission File Number) |
| (IRS Employer Identification No.) |
275 Shoreline Drive, Suite 150 Redwood City, California 94065 |
| 94065 |
(Address of Principal Executive Offices) |
| (Zip Code) |
Registrant’s Telephone Number, Including Area Code: (416) 214-3678 | ||
| ||
| ||
(Former Name or Former Address, if Changed Since Last Report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (seeGeneral Instruction A.2. below):
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 | Other Events |
On October 18, 2016, Biotricity, Inc., a Nevada corporation (the “Registrant”), announced that it has received a 510(k) clearance from the U.S. Food and Drug Administration for the software component of its bioflux solution.
A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01 | Financial Statements and Exhibits |
(d)
Exhibits. The exhibit listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K:
Exhibit No. | Description | ||
|
| ||
99.1 | Press Release |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: October 18, 2016
| BIOTRICITY INC. | |
|
|
|
| By: | /s/ Waqaas Al-Siddiq |
|
| Waqaas Al-Siddiq |
|
| Chief Executive Officer |
3